PharmaGap to Host Investor Conference Call

PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") will host an investor conference call on Tuesday, October 4 at 3:00 p.m. until 4:00 p.m. Eastern Time. Mr. Roderick Bryden, Chairman of the Board and largest shareholder, Mr. Robert McInnis, President and Chief Executive Officer, and Dr. Kenneth Sokoll, Vice President Clinical Development and Chief Operating Officer will respond to questions from participants.

To participate in the call, please call (613) 787-5141, or toll free (866) 797-9098, and enter the participant passcode 7211580 when so directed. Please connect several minutes prior to 3:00 p.m. so that the call may begin promptly at 3:00 Eastern time.

The purpose of the call is to respond to a range of questions regarding the Company's business and drug development program that have been provided to the Company by a number of shareholders. Specific additional questions may be submitted in advance to the moderator of the call, Mr. Andrew Bryenton (Andrew.bryenton@yahoo.com).

About PharmaGap Inc.

PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug that has been shown to be highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.

Forward Looking Statements

This news release contains certain statements that constitute forward-looking statements as they relate to the Company and its management. Forward-looking statements are not historical facts but represent management's current expectations of future events, and can be identified by words such as "believe", "expects", "will", "intends", "plans", "projects", "anticipates", "estimates", "continues", and similar expressions. Although management believes that expectations represented in such forward-looking statements are reasonable, there can be no assurance that they will prove to be correct.

By their nature, forward-looking statements include assumptions and are subject to inherent risks and uncertainties that could cause actual future results, conditions, actions or events to differ materially from those in the forward-looking statements. If and when forward-looking statements are set out in this news release, PharmaGap will also set out the material risk factors or assumptions used to develop the forward-looking statements. Except as expressly required by applicable securities laws, the Company assumes no obligation to update or revise any forward-looking statements. The future outcomes that relate to forward-looking statements may be influenced by many factors, including, but not limited to: results of ongoing product testing and development; regulatory approvals required to complete development of products; ability to manufacture product at quality and scale for human use on an economically sound basis; patient reimbursement by private and public health insurance programs; unintended side effects of products; competitive products; product liability; intellectual property; reliance on key personnel; risks of future legal proceedings; income tax matters; availability and terms of financing; distribution of securities; effect of market interest rates on price of securities, and potential dilution.

Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.

Contacts: PharmaGap Inc. Robert McInnis President & CEO 613-990-9551bmcinnis@pharmagap.com

Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From May 2024 to Jun 2024